Taiwan Advance Bio-Pharmaceutical Profit Margin

Taiwan Advance Bio-Pharmaceutical (4186.TWO) currently reports a profit margin of 5.43% as of June 2026. That compares with -3.2% in the prior-year period — up 269.9% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Taiwan Advance Bio-Pharmaceutical's profit margin history and peer comparisons.

Taiwan Advance Bio-Pharmaceutical's profit margin increased from -3.2% to 5.43% — a 269.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Taiwan Advance Bio-Pharmaceutical's profit margin of 5.43% is lower than the Healthcare sector average of 21.34%. That is roughly 74.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Taiwan Advance Bio-Pharmaceutical's current 5.43% should be judged against Healthcare norms (sector average: 21.34%) and against 4186.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 5.43%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Taiwan Advance Bio-Pharmaceutical, and consider following 4186.TWO for alerts when major investors trade the stock.